Marksans Pharma's UK Subsidiary, Relonchem, Receives Marketing Authorization for Metformin Hydrochloride Prolonged Release Tablets

Marksans Pharma Limited, a Mumbai-based pharmaceutical company, announces that its wholly owned UK subsidiary, Relonchem Limited, has received Marketing Authorization from UK MHRA for Metformin Hydrochloride Relonchem 500 mg, 750 mg, and 1000 mg Prolonged Release Tablets. This authorization marks a significant milestone for Marksans Pharma, expanding its product portfolio in the UK market. The company's manufacturing facilities in India, USA, and UK are approved by several leading regulatory agencies, including USFDA, UKMHRA, and Australian TGA. Marksans Pharma is engaged in Research, Manufacturing & Marketing of generic pharmaceutical formulations in the global markets, with a robust product portfolio spread over major therapeutic segments of CVS, CNS, Anti-diabetic, Pain Management, Gastroenterological, and Anti-allergies.